What type of drug is Vitrakvi (larotrectinib)?
Medically reviewed by drugclasses.com. Last updated on Nov 22, 2023.
Vitrakvi is an inhibitor of the tropomyosin receptor kinases, TRKA, TRKB, and TRKC. Vitrakvi is used to treat adults and children with solid tumors.
In November 2018 the U.S. Food and Drug Administration (FDA) approved Vitrakvi (larotrectinib), an oral treatment for adults and children with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Vitrakvi is the first TRK inhibitor for cancers that express this mutation.
- NTRK genes may be fused to other genes, leading to a TRK fusion protein that results in solid tumors across various sites.
- NTRK fusions are rare cancers but arise in many places in the body, and include soft tissue sarcoma, salivary gland cancer, infantile fibrosarcoma, thyroid cancer and lung cancer.
- Vitrakvi is also the second approval for cancers based on a common gene mutation rather than site of origin; Keytruda (pembrolizumab) was the first.
Read next
What is the strongest chemotherapy drug for breast cancer?
Doxorubicin is considered one of the strongest chemotherapy drugs for breast cancer ever invented. It can kill cancer cells at every point in their life cycle, and it's used to treat a wide variety of cancers, not just breast cancer. Doxorubicin is also known as “The Red Devil” because it is a clear bright red color. It can cause your urine or other body fluids to turn a reddish color for 1 to 2 days after a dose is given, which is normal and temporary. Continue reading
Is small cell or non-small cell lung cancer worse?
Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading
Is non-small cell lung cancer hereditary?
A hereditary family history of lung cancer is one of the many risk factors for developing non-small cell lung cancer. About 8% of lung cancers are thought to be inherited or linked to gene changes, but smoking and air pollution remain the primary causes of lung cancer. Continue reading
Related medical questions
- How aggressive is non-small cell lung cancer?
- Does smoking cause non-small cell lung cancer?
- What type of prostate cancer is Erleada used to treat?
- What type of lung cancer is Vizimpro used to treat?
- What type of cancer is Tecentriq used to treat?
- What type of cancer is Daurismo (glasdegib) used to treat?
- Oxycodone vs Hydrocodone - How do they compare?
- Does omeprazole cause cancer?
- Why is Xanax so addictive?
- How do you increase platelet count during chemotherapy?
- What are monoclonal antibodies?
- Vicodin vs Percocet: What's the difference?
- How do I know if immunotherapy is working?
- Why give Taxol (Paxel) before carboplatin?
- What are anti-VEGF drugs (VEGF inhibitors)?
- What is Quercetin and what are its health benefits?
- My stool has changed color. What does it mean?
- How do I know if Aldara is working for skin cancer?
- How does Ibrance kill cancer?
- Does Xolair cause cancer?
- Does Skyrizi cause cancer?
- Is food coloring bad for you?
- Can Tymlos cause bone cancer?
- What is a chemotherapy regimen?
- How do Herceptin (trastuzumab) and Perjeta (pertuzumab) work together?
- How does chemotherapy affect the cell cycle?
- How much does Tecartus cost?
- How does carboplatin stop cancer?
- How is immunotherapy administered?
- How are Inlyta and Keytruda used in kidney cancer?
Drug information
Related support groups
- Vitrakvi (1 questions, 3 members)
- Larotrectinib (1 questions, 3 members)
- Cancer (175 questions, 641 members)
- Solid Tumors (4 questions, 7 members)